Genomma Lab Internacional S.A.B. de C.V Asset Resilience Ratio
Genomma Lab Internacional S.A.B. de C.V asset resilience ratio. Genomma Lab Internacional S.A.B. de C.V (LABB) has an Asset Resilience Ratio of 0.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Genomma Lab Internacional S.A.B. de C.V defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genomma Lab Internacional S.A.B. de C.V (2007–2025)
Asset resilience ratio of Genomma Lab Internacional S.A.B. de C.V from 2007 to 2025. This chart shows how Genomma Lab Internacional S.A.B. de C.V's Asset Resilience Ratio has changed over time. Read LABB total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genomma Lab Internacional S.A.B. de C.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LABB total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$213.62 Million | 0.9% |
| Total Liquid Assets | MX$213.62 Million | 0.90% |
Asset Resilience Insights
- Limited Liquidity: Genomma Lab Internacional S.A.B. de C.V maintains only 0.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genomma Lab Internacional S.A.B. de C.V Industry Peers by Asset Resilience Ratio
Compare Genomma Lab Internacional S.A.B. de C.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Genomma Lab Internacional S.A.B. de C.V Asset Resilience Ratio by Year (2007–2025)
Genomma Lab Internacional S.A.B. de C.V asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Genomma Lab Internacional S.A.B. de C.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.90% | MX$213.62 Million ≈ $12.29 Million |
MX$23.83 Billion ≈ $1.37 Billion |
+0.53pp |
| 2024-12-31 | 0.37% | MX$89.25 Million ≈ $5.14 Million |
MX$24.08 Billion ≈ $1.39 Billion |
-0.51pp |
| 2023-12-31 | 0.89% | MX$183.23 Million ≈ $10.55 Million |
MX$20.70 Billion ≈ $1.19 Billion |
-0.07pp |
| 2022-12-31 | 0.95% | MX$205.93 Million ≈ $11.85 Million |
MX$21.61 Billion ≈ $1.24 Billion |
+0.81pp |
| 2017-12-31 | 0.15% | MX$23.21 Million ≈ $1.34 Million |
MX$15.89 Billion ≈ $914.23 Million |
-0.15pp |
| 2015-12-31 | 0.30% | MX$52.07 Million ≈ $3.00 Million |
MX$17.63 Billion ≈ $1.01 Billion |
+0.23pp |
| 2014-12-31 | 0.07% | MX$17.84 Million ≈ $1.03 Million |
MX$25.43 Billion ≈ $1.46 Billion |
+0.02pp |
| 2013-12-31 | 0.05% | MX$8.13 Million ≈ $467.65K |
MX$17.35 Billion ≈ $998.66 Million |
-0.21pp |
| 2012-12-31 | 0.25% | MX$32.75 Million ≈ $1.88 Million |
MX$12.99 Billion ≈ $747.73 Million |
-6.55pp |
| 2007-12-31 | 6.81% | MX$81.26 Million ≈ $4.68 Million |
MX$1.19 Billion ≈ $68.72 Million |
-- |
About Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products t… Read more